Cellular pathophysiology of cystic kidney disease: Insight into future therapies

International Journal of Developmental Biology

Volumn 43, Issue 5, 1999, Pages 457-461

  Avner, Ellis D ^a   Woychik, Richard P ^a   Dell, Katherine Macrae ^a   Sweeney, William E ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Epidermal growth factor receptor; Gene therapy; Polycystic kidney disease

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; CYTOLOGY; GENE MUTATION; GENE THERAPY; GENETIC COMPLEMENTATION; HUMAN; KIDNEY POLYCYSTIC DISEASE; MODEL; MOLECULAR CLONING; MOLECULAR GENETICS; MOUSE; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ANIMALS; GENE THERAPY; HUMANS; MEMBRANE PROTEINS; MICE; POLYCYSTIC KIDNEY DISEASES; PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRPP CATION CHANNELS; TUMOR SUPPRESSOR PROTEINS; UROTHELIUM;

ANIMALIA;

EID: 0032834946     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. ARNOULD, T., KIM, E., TSIOKAS, L., JOCHIMSEN, F., GRUNING, W., CHANG, J.D. and WALZ, G. (1998). The polycystic kidney disease 1 gene product mediates protein kinase C-dependent and c-jun N-terminal kinase-dependent activation of the transcription factor AP-1. J. Biol. Chem. 273: 6013-6018.
2. AVNER, E.D., SWEENEY, W.E. and WOYCHIK, R.P. (1995). Inhibition of epidermal growth factor receptor activity modulates collecting tubule cystogenesis in vitro. J. Am. Soc. Nephrol. 6: 690.
3. CALVET, J.P. (1998). Molecular genetics of polycystic kidney disease. J. Nephrol. 11: 24-34.
4. DU, J. and WILSON, P.D. (1995). Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am. J. Physiol. 269: C487-C495.
5. LEVITZKI, A. (1992). Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J. 6: 3275-3282.
6. MCDONALD, R.A., WATKINS, S.L. and AVNER, E.D. (1999). Polycystic kidney disease. In Pediatric Nephrology, 4th Edition (eds. T.M. Barratt, E.D. Avner, W. Harmon). Lippincott, Williams and Wilkins, Baltimore, pp. 459-474.
7. MURCIA, N.S., SWEENEY, W.E. and AVNER, E.D. (1999). New insights into the molecular pathophysiology of polycystic kidney disease. Kidney Int. 55: 1187-1197.
8. MURCIA, N.S., WOYCHIK, R.P. and AVNER, E.D. (1998). The molecular biology of polycystic kidney disease. Pediatr. Nephrol. 12: 721-726.
9. O'NEILL, M. (1998). Dramatic research progress is setting the stage for clinical trials in polycystic kidney disease. Contemporary Dialysis and Nephrology 19: 38-41.
10. ORELLANA, S. and AVNER, E.D. (1995). Cystic maldevelopment of the kidney. Semin. Nephrol. 15: 341-352.
11. PUGH, J., SWEENEY, W.E. and AVNER, E.D. (1995). The tyrosine kinase activity of the EGF receptor in murine metanephric organ culture. Kidney Int. 47: 774-781.
12. RICHARDS, W.G., SWEENEY, W.E., YODER B.K., WILKINSON, J.E., WOYCHIK, R.P. and AVNER, E.D. (1998). Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J. Clin. Invest. 101: 935-939.
13. SULLIVAN, L.P., WALLACE, D.P. and GRANTHAM, J.J. (1998). Chloride and fluid secretion in polycystic kidney disease. J. Am. Soc. Nephrol. 9: 903-916.
14. SWEENEY, W.E. and AVNER, E.D. (1998). Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease. Am. J. Physiol. 44: F387-F394.
15. TORRES, V.E. (1998). New insights into polycystic kidney disease and its treatment. Curr. Opin. Nephrol. Hypertens. 7: 159-169.
16. TSIOKAS, L., KIM, E., ARNOULD, T., SUKHATME, V.P. and WALZ, G. (1997). Homo- and heterodimeric interactions between the gene products of PKD1 and PKD2. Proc. Natl. Acad. Sci. USA 94: 6965-6970.
17. WU, C.H., WILSON, J.M. and WU, G.Y. (1989). Targeting genes: delivery and persistent expression of a foreign gene driven by mammaliam regulatory elements in vivo. J. Biol. Chem. 264: 16985-16987.
18. YODER, B.K., RICHARDS, W.G., SOMMARDAHL, C.S., SWEENEY, W.E., MICHAUD E.J., WILKINSON J.E., AVNER, E.D. and WOYCHIK, R.P. (1996). Functional correction of the renal defects in a mouse model for ARPKD through expression of the cloned wild-typeTg737 cDNA. Kidney Int. 50: 1240-1248
19. YODER, B.K., RICHARDS, W.G., SOMMARDAHL, C.S., SWEENEY, W.E., MICHAUD, E.J., WILKINSON, J.E., AVNER, E.D. and WOYCHIK, R.P. (1937a). Differential rescue of the renal and hepatic disease in an ARPKD mouse mutant: a new model to study the liver lesion. Am. J. Pathol. 150: 2231-2241.
20. YODER, B.K., WILKINSON, J.E., AVNER, E.D. and WOYCHIK, R.P. (1997b). The Tg737 protein interacts with polycystin and proteins controlling epithelial polarity, EGFR stability and cellular differentiation. J. Am. Soc. Nephrol. 8: 386A. (Abstr.).